U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H42O8
Molecular Weight 530.6497
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROSCILLARIDIN

SMILES

[H][C@@]6(O[C@H]1CC[C@@]2(C)C(CC[C@]3([H])[C@]2([H])CC[C@]4(C)[C@H](CC[C@]34O)C5=COC(=O)C=C5)=C1)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O

InChI

InChIKey=MYEJFUXQJGHEQK-ALRJYLEOSA-N
InChI=1S/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3/t16-,19-,20+,21-,22+,24-,25+,26+,27-,28-,29+,30-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including, http://www.ijppsjournal.com/Vol5Issue4/7570.pdf, http://www.ptfarm.pl/pub/File/Acta_Poloniae/2005/4/319.pdf

Proscillaridin is a substance that was used in Europe for the treatment of heart failure and atrial fibrillation. Proscillaridin belongs to glycosides and acts as a Na+/K+-ATPase inhibitor.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 0.17 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
TALUSIN

Approved Use

Unknown
Primary
Approved
8429
TALUSIN

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure.
2005 Jan
Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors.
2007 May 9
Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.
2010 Sep 27
Patents

Patents

JPH0320296A
1

Sample Use Guides

In Vivo Use Guide
The typical dose for current indication (p.o.) is about 1.5 mg/day.
Route of Administration: Oral
In Vitro Use Guide
Aggregation of platelets, preincubated 20 min with 100 uM and 200 uM proscillaridin was studied in vitro. Proscillaridin induced, in adose and time dependent manner, aprocoagulant response in platelets. Maximal procoagulant response was observed at 100 uM.
Name Type Language
PROSCILLARIDIN
INN   JAN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
PROSCILLARIDIN [MI]
Common Name English
NSC-7521
Code English
proscillaridin [INN]
Common Name English
Proscillaridin [WHO-DD]
Common Name English
PROSCILLARIDIN [MART.]
Common Name English
PROSCILLARIDIN [USAN]
Common Name English
TALUSIN
Brand Name English
BUFA-4,20,22-TRIENOLIDE, 3-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-14-HYDROXY-, (3.BETA.)-
Common Name English
A-32686
Code English
PROSCILLARIDIN [JAN]
Common Name English
Proscillaridin A
Common Name English
((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-14-HYDROXYBUFA-4,20,22-TRIENOLIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78322
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
WHO-VATC QC01AB51
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
WHO-VATC QC01AB01
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
WHO-ATC C01AB01
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
WHO-ATC C01AB51
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
Code System Code Type Description
FDA UNII
KC6BL281EN
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
ChEMBL
CHEMBL600325
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
MERCK INDEX
m9255
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID5023532
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
RXCUI
8795
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY RxNorm
CAS
466-06-8
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
DRUG CENTRAL
2313
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
SMS_ID
100000092170
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
WIKIPEDIA
PROSCILLARIDIN
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
DRUG BANK
DB13307
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
INN
2242
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
NSC
7521
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
PUBCHEM
5284613
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
NCI_THESAURUS
C84121
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
MESH
D011442
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
EVMPD
SUB10131MIG
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
ECHA (EC/EINECS)
207-370-4
Created by admin on Fri Dec 15 15:20:41 GMT 2023 , Edited by admin on Fri Dec 15 15:20:41 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of PROSCILLARIDIN
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966